Licensing Deals May Become More Adversarial Following MedImmune Ruling
Executive Summary
The Supreme Court's ruling that MedImmune is entitled to challenge a patent it is licensing from Genentech will likely create a more contentious environment for parties negotiating licensing deals
You may also be interested in...
Latest PTO Ruling On Cabilly May Offer Ray Of Hope To Genentech Licensees
The U.S. Patent and Trademark Office's rejection of Genentech's Cabilly patent was little surprise after the office's non-final rejection in 2005, but it may make Genentech's licensees more upbeat now that an end to royalty payments is a small step closer
Latest PTO Ruling On Cabilly May Offer Ray Of Hope To Genentech Licensees
The U.S. Patent and Trademark Office's rejection of Genentech's Cabilly patent was little surprise after the office's non-final rejection in 2005, but it may make Genentech's licensees more upbeat now that an end to royalty payments is a small step closer
Patent Reform Bill Gets Cool Reception From Rx Industry; Damage Cap Is Worry
A new patent reform bill introduced in Congress is likely to undergo revisions in the face of criticism from the pharmaceutical industry